{
  "meta": {
    "title": "21_Diabetes_Mellitus",
    "url": "https://brainandscalpel.vercel.app/21-diabetes-mellitus-35781d5c.html",
    "scrapedAt": "2025-11-30T06:57:05.490Z"
  },
  "questions": [
    {
      "id": 94484,
      "choices": [
        {
          "id": 225916,
          "text": "It is an autoimmune disease"
        },
        {
          "id": 225917,
          "text": "It is insulin dependent diabetes"
        },
        {
          "id": 225918,
          "text": "It is not associated with thyroid disorders"
        },
        {
          "id": 225919,
          "text": "Insulin resistance is the hallmark of the disease pathogenesis"
        }
      ],
      "text": "Which of the following statements is true for type 1 diabetes?",
      "unique_key": "Q7057236",
      "question_audio": null,
      "question_video": null,
      "map_id": 34067023,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) It is an autoimmune disease. Type 1 diabetes (T1D) is primarily an autoimmune disorder where the body's immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. This destruction leads to a lack of insulin production, requiring lifelong insulin therapy. The autoimmune nature of T1D is supported by the presence of certain antibodies (e.g., islet cell antibodies, insulin autoantibodies) in many patients. B. It is insulin-dependent diabetes While this statement is true, it is less specific and less accurate than A. Type 1 diabetes is indeed insulin-dependent, meaning patients need insulin to survive because their bodies cannot produce insulin. However, the more defining feature of T1D is its autoimmune origin, which is captured better in option A. C. It is not associated with thyroid disorders This option is incorrect because Type 1 diabetes is frequently associated with other autoimmune disorders, including thyroid disorders like Hashimoto's thyroiditis and Graves' disease. The presence of multiple autoimmune diseases in T1D patients suggests a genetic predisposition to autoimmune conditions. D. Insulin resistance is the hallmark of the disease pathogenesis This option is incorrect because insulin resistance is more characteristic of Type 2 diabetes, not Type 1 diabetes. In Type 1 diabetes, the main issue is the destruction of pancreatic beta cells, leading to an absolute insulin deficiency, rather than insulin resistance.",
      "correct_choice_id": 225916,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47074711704441182/47074711704441182.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47074711704441182/47074711704441182.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94485,
      "choices": [
        {
          "id": 225920,
          "text": "Recognised endocrine causes of diabetes include acromegaly and cushing’s syndrome"
        },
        {
          "id": 225921,
          "text": "The majority of type 2 diabetes mellitus patients die from cardiovascular disease"
        },
        {
          "id": 225922,
          "text": "Fasting blood sugar more than 126 establishes diagnosis of diabetes"
        },
        {
          "id": 225923,
          "text": "Patients with type 2 diabetes are more prone to ketoacidosis as compared to type 1"
        }
      ],
      "text": "In diabetes all of the following statement are correct EXCEPT",
      "unique_key": "Q4804858",
      "question_audio": null,
      "question_video": null,
      "map_id": 34960209,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Patients with type 2 diabetes are more prone to ketoacidosis as compared to type 1. This statement is incorrect because Type 1 diabetes patients are more prone to diabetic ketoacidosis (DKA) due to the absolute lack of insulin production, which leads to the accumulation of ketones in the body. On the other hand, Type 2 diabetes is characterized by insulin resistance and some insulin secretion, which typically prevents the development of DKA. Instead, patients with Type 2 diabetes are more likely to develop hyperosmolar hyperglycemic state (HHS), a condition that is different from DKA. A. Recognized endocrine causes of diabetes include acromegaly and Cushing’s syndrome This option is correct. Both acromegaly (due to excess growth hormone) and Cushing’s syndrome (due to excess cortisol) can lead to secondary diabetes by promoting insulin resistance. Elevated levels of these hormones interfere with normal glucose metabolism, thus increasing blood sugar levels. B. The majority of type 2 diabetes mellitus patients die from cardiovascular disease This option is correct. Cardiovascular disease (CVD) is the leading cause of death in patients with Type 2 diabetes due to the combination of insulin resistance, obesity, hypertension, and dyslipidemia, all of which increase the risk of atherosclerosis and other cardiovascular events. C. Fasting blood sugar more than 126 establishes diagnosis of diabetes This option is correct. According to the American Diabetes Association (ADA), a fasting blood sugar level greater than 126 mg/dL (on two separate occasions) is considered diagnostic for diabetes. This criterion helps identify individuals with impaired glucose regulation and insulin secretion, which are characteristic of diabetes.",
      "correct_choice_id": 225923,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43671121704441203/43671121704441203.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43671121704441203/43671121704441203.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94486,
      "choices": [
        {
          "id": 225924,
          "text": "Lisinopril"
        },
        {
          "id": 225925,
          "text": "Hydrocholrthiazide"
        },
        {
          "id": 225926,
          "text": "Losartan"
        },
        {
          "id": 225927,
          "text": "Enalapril"
        }
      ],
      "text": "A 52 year old female patient is suffering from type 2 diabetes mellitus and hypertension. Which of the following antihypertensive drug should not be used in such patients?",
      "unique_key": "Q8841860",
      "question_audio": null,
      "question_video": null,
      "map_id": 34928321,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Hydrochlorothiazide. Thiazide diuretics, like hydrochlorothiazide, should generally be avoided or used with caution in patients with Type 2 diabetes because they can increase blood sugar levels. This effect can worsen glycemic control in diabetic patients, leading to poor diabetes management. Additionally, thiazide diuretics may contribute to electrolyte imbalances, such as low potassium levels, which can exacerbate other complications in diabetic patients. A. Lisinopril This option is correct for patients with Type 2 diabetes and hypertension. Lisinopril, an ACE inhibitor, is often recommended for diabetic patients with hypertension because it can help protect the kidneys. ACE inhibitors are beneficial in preventing diabetic nephropathy and can reduce albuminuria, a common complication of diabetes. They also have a favorable effect on blood pressure control and overall cardiovascular health. C. Losartan This option is also correct. Losartan, an angiotensin II receptor blocker (ARB), is another medication that can be used safely in diabetic patients with hypertension. Like ACE inhibitors, ARBs can help protect the kidneys from damage caused by diabetes and improve blood pressure control. They are often used in patients with diabetic nephropathy or at risk for kidney complications. D. Enalapril This option is also correct. Enalapril, another ACE inhibitor, is safe and effective in patients with both Type 2 diabetes and hypertension. Similar to lisinopril, enalapril can help with kidney protection and is beneficial in controlling blood pressure in diabetic individuals.",
      "correct_choice_id": 225925,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48986181704441467/48986181704441467.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48986181704441467/48986181704441467.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94487,
      "choices": [
        {
          "id": 225928,
          "text": "Fasting blood sugar"
        },
        {
          "id": 225929,
          "text": "Random blood sugar"
        },
        {
          "id": 225930,
          "text": "D-Xylose test"
        },
        {
          "id": 225931,
          "text": "Fructossamine assay"
        }
      ],
      "text": "Which of the following is not a test for diabetes mellitus?",
      "unique_key": "Q7772468",
      "question_audio": null,
      "question_video": null,
      "map_id": 34453648,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) D-Xylose test. The D-Xylose test is not a diagnostic test for diabetes mellitus. It is used to assess intestinal malabsorption and absorption of carbohydrates. In this test, the patient ingests D-xylose, and the level of D-xylose in the urine or blood is measured to evaluate how well the body absorbs it. This test is not specific for diagnosing diabetes, as it focuses on digestive function rather than glucose metabolism. A. Fasting blood sugar This option is correct. Fasting blood sugar (FBS) is a standard diagnostic test for diabetes mellitus. A FBS level greater than 126 mg/dL (on two separate occasions) is a diagnostic criterion for diabetes according to the American Diabetes Association (ADA). It measures the level of glucose in the blood after fasting for at least 8 hours. B. Random blood sugar This option is correct. Random blood sugar (RBS) is another test used to diagnose diabetes. A random blood glucose level greater than 200 mg/dL, along with symptoms of hyperglycemia (such as increased thirst and urination), can confirm a diagnosis of diabetes, even without fasting. D. Fructosamine assay This option is correct. The fructosamine assay measures the levels of fructosamine in the blood, which is a marker of short-term glucose control (over 2-3 weeks). It is used in situations where HbA1c cannot be reliably measured (e.g., in patients with anemia or other hemoglobinopathies). It is a valid test to assess glucose control in diabetes, though not used for diagnosis.",
      "correct_choice_id": 225930,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52270141704441729/52270141704441729.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52270141704441729/52270141704441729.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94488,
      "choices": [
        {
          "id": 225932,
          "text": "Fasting plasma glucose > 100 mg/dl and 2 hour post-prandial more than 140 mg/dl"
        },
        {
          "id": 225933,
          "text": "Fasting plasma glucose > 125 mg/dl and 2 hour post-prandial more than 199 mg/dl"
        },
        {
          "id": 225934,
          "text": "Symptoms of diabetes plus random blood glucose of 190 mg/dl"
        },
        {
          "id": 225935,
          "text": "Glycosylated haemoglobin > 6.5%"
        }
      ],
      "text": "Which of the following findings can establish a diagnosis of diabetes mellitus?",
      "unique_key": "Q1671123",
      "question_audio": null,
      "question_video": null,
      "map_id": 34527103,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Glycosylated hemoglobin > 6.5%. Glycosylated hemoglobin (HbA1c) levels above 6.5% are diagnostic for diabetes mellitus. The HbA1c test reflects the average blood glucose levels over the past 2-3 months. An HbA1c level of 6.5% or higher is one of the diagnostic criteria for diabetes, as recommended by the American Diabetes Association (ADA). This test provides a long-term view of glucose control, which is particularly helpful for diagnosing diabetes without requiring a fasting state or post-meal measurement. A. Fasting plasma glucose > 100 mg/dL and 2-hour post-prandial more than 140 mg/dL This option is incorrect. Fasting plasma glucose greater than 100 mg/dL indicates impaired fasting glucose (IFG), which is a prediabetic condition, not diabetes. A 2-hour post-prandial glucose level greater than 140 mg/dL is suggestive of impaired glucose tolerance (IGT), which is also a form of prediabetes, not a diagnosis of diabetes. For a diagnosis of diabetes, a fasting plasma glucose greater than 126 mg/dL or a 2-hour post-prandial greater than 200 mg/dL is required. B. Fasting plasma glucose > 125 mg/dL and 2-hour post-prandial more than 199 mg/dL This option is partially correct but incomplete. While a fasting plasma glucose > 125 mg/dL and a 2-hour post-prandial glucose > 199 mg/dL are both diagnostic of diabetes, the ADA requires a confirmed second test on a different day to establish the diagnosis. A single instance of these elevated values does not constitute a definitive diagnosis; confirmation is necessary. Therefore, while it points to a diagnosis, it is not fully sufficient on its own without further testing. C. Symptoms of diabetes plus random blood glucose of 190 mg/dL This option is correct but needs additional context. Symptoms of diabetes (e.g., polyuria, polydipsia, unexplained weight loss) along with a random blood glucose level of 200 mg/dL or higher is diagnostic of diabetes. However, a random blood glucose of 190 mg/dL alone, even with symptoms, is not diagnostic. For diabetes diagnosis, a random blood glucose of 200 mg/dL or more is required when symptoms are present.",
      "correct_choice_id": 225935,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55494471704441910/55494471704441910.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55494471704441910/55494471704441910.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94489,
      "choices": [
        {
          "id": 225936,
          "text": "Fasting plasma sugar > 126 mg/dl"
        },
        {
          "id": 225937,
          "text": "Random blood sugar > 200 mg/dl"
        },
        {
          "id": 225938,
          "text": "Fasting blood sugar < 140 mg/dl and 2 hours after glucose load < 200 mg/dl"
        },
        {
          "id": 225939,
          "text": "2 hours after glucose load 140-199 mg/dl, fasting blood sugar < 125 mg/dl"
        }
      ],
      "text": "Impaired glucose tolerance on an oral GTT is indicated by",
      "unique_key": "Q8515324",
      "question_audio": null,
      "question_video": null,
      "map_id": 34633412,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) 2 hours after glucose load 140-199 mg/dL, fasting blood sugar 126 mg/dL This option is incorrect. A fasting plasma glucose level greater than 126 mg/dL is a diagnostic criterion for diabetes, not for impaired glucose tolerance. For IGT, fasting plasma glucose should be less than 126 mg/dL. B. Random blood sugar > 200 mg/dL This option is incorrect. A random blood sugar greater than 200 mg/dL is also a diagnostic criterion for diabetes, especially when accompanied by symptoms of hyperglycemia. However, IGT is diagnosed based on specific glucose measurements during an OGTT, not a random blood glucose test. C. Fasting blood sugar < 140 mg/dL and 2 hours after glucose load < 200 mg/dL This option is incorrect because it describes normal glucose metabolism rather than impaired glucose tolerance. For normal glucose tolerance, the fasting blood sugar is less than 100 mg/dL, and the 2-hour post-glucose load is less than 140 mg/dL.",
      "correct_choice_id": 225939,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60494111704441921/60494111704441921.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60494111704441921/60494111704441921.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94490,
      "choices": [
        {
          "id": 225940,
          "text": "Morning hyperglycemia with midnight hypoglycaemia"
        },
        {
          "id": 225941,
          "text": "Morning hypoglycaemia with midnight hyperglycemia"
        },
        {
          "id": 225942,
          "text": "Morning hyperglycemia with midnight hyperglycemia"
        },
        {
          "id": 225943,
          "text": "Morning hypoglycaemia due to excess insulin"
        }
      ],
      "text": "Which of the following statements about dawn phenomenon is true?",
      "unique_key": "Q5285026",
      "question_audio": null,
      "question_video": null,
      "map_id": 34304392,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Morning hyperglycemia with midnight hyperglycemia. Dawn phenomenon refers to an increase in blood glucose levels that occurs in the early morning hours (typically between 2-8 AM), which is caused by a combination of physiological hormonal fluctuations (such as increased secretion of growth hormone, cortisol, and catecholamines) that induce insulin resistance and lead to elevated blood glucose levels. This phenomenon typically results in morning hyperglycemia. Midnight hyperglycemia can also occur due to the counter-regulatory hormonal effects during the night, contributing to the overall elevated glucose levels. A. Morning hyperglycemia with midnight hypoglycemia This option is incorrect. The dawn phenomenon is characterized by morning hyperglycemia, not hypoglycemia. It is due to hormonal changes overnight that increase insulin resistance and promote glucose production. Midnight hypoglycemia is more likely to be associated with insulin treatment or excessive insulin dosing during the night, but not with the dawn phenomenon. B. Morning hypoglycemia with midnight hyperglycemia This option is incorrect. Morning hypoglycemia is typically not seen in the dawn phenomenon. Hypoglycemia in the morning can occur in cases of insulin overdose or excessive nocturnal insulin, but not as a characteristic of the dawn phenomenon. The dawn phenomenon primarily causes morning hyperglycemia due to increased glucose production overnight. D. Morning hypoglycemia due to excess insulin This option is incorrect. Morning hypoglycemia is not a feature of the dawn phenomenon. While excess insulin could cause hypoglycemia during the night or early morning, this would not be classified as the dawn phenomenon. Instead, the dawn phenomenon results in hyperglycemia due to hormonal changes that induce insulin resistance, not insulin excess.",
      "correct_choice_id": 225942,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36334041704443689/36334041704443689.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36334041704443689/36334041704443689.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94491,
      "choices": [
        {
          "id": 225944,
          "text": "Amyotrophy"
        },
        {
          "id": 225945,
          "text": "Mononeuropathy"
        },
        {
          "id": 225946,
          "text": "Symmetric sensory neuropathy"
        },
        {
          "id": 225947,
          "text": "Autonomic neuropathy"
        }
      ],
      "text": "The characteristic and common presentation of diabetic neuropathy is:",
      "unique_key": "Q1864245",
      "question_audio": null,
      "question_video": null,
      "map_id": 34165547,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Symmetric sensory neuropathy. Diabetic neuropathy is the most common complication of diabetes mellitus, particularly in patients with poorly controlled blood sugar levels over time. Symmetric sensory neuropathy is the most characteristic and common form of diabetic neuropathy, presenting with bilateral symptoms, such as tingling, numbness, and pain in the distal parts of the body, especially in the feet and legs. This type of neuropathy typically affects sensory fibers and is often referred to as \"stocking-glove\" neuropathy because of its distribution. The condition is caused by prolonged hyperglycemia, which leads to nerve damage over time. A. Amyotrophy This option is incorrect. Amyotrophy refers to muscle wasting or weakness, which can occur in certain conditions such as diabetic amyotrophy or diabetic lumbosacral radiculoplexus neuropathy. However, it is not the most common or characteristic presentation of diabetic neuropathy. Amyotrophy typically involves more localized muscle weakness and is less frequently seen than symmetric sensory neuropathy. B. Mononeuropathy This option is incorrect. Mononeuropathy refers to damage to a single nerve or nerve group, leading to symptoms like pain, weakness, or numbness in a specific area. It can occur in diabetes but is less common than symmetric sensory neuropathy. Mononeuropathy often affects nerves like the cranial nerves (especially the oculomotor nerve), causing problems like double vision or pain behind the eyes, but it does not represent the typical pattern of diabetic neuropathy. D. Autonomic neuropathy This option is incorrect. Autonomic neuropathy involves damage to the autonomic nerves, which control involuntary functions such as blood pressure regulation, heart rate, digestion, and urinary function. While autonomic neuropathy is a serious complication of diabetes, it is not as common as symmetric sensory neuropathy, which specifically affects sensory nerves in the extremities. Symptoms of autonomic neuropathy include gastroparesis, orthostatic hypotension, and bladder dysfunction, but it is less commonly the first presentation of diabetic neuropathy.",
      "correct_choice_id": 225946,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7951281704443702/7951281704443702.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7951281704443702/7951281704443702.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94492,
      "choices": [
        {
          "id": 225948,
          "text": "Diffuse glomerulosclerosis"
        },
        {
          "id": 225949,
          "text": "Nodular glomerulosclerosis"
        },
        {
          "id": 225950,
          "text": "Armani-Ebstein reaction"
        },
        {
          "id": 225951,
          "text": "Fibrin caps"
        }
      ],
      "text": "The most characteristic finding in diabetic nephropathy is:",
      "unique_key": "Q3890652",
      "question_audio": null,
      "question_video": null,
      "map_id": 34463875,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Nodular glomerulosclerosis. Nodular glomerulosclerosis is the most characteristic finding in diabetic nephropathy, which is a common and serious complication of diabetes mellitus. This condition primarily affects the glomeruli in the kidneys, leading to progressive kidney damage. Nodular glomerulosclerosis, also known as Kimmelstiel-Wilson disease, is marked by the presence of nodular lesions in the glomerular capillaries, which are typically observed as eosinophilic deposits. These nodules are a hallmark feature of diabetic nephropathy and contribute to the progressive decline in kidney function over time. A. Diffuse glomerulosclerosis This option is incorrect. While diffuse glomerulosclerosis can be observed in diabetic nephropathy, it is not the most characteristic finding. Diffuse glomerulosclerosis refers to a general thickening of the glomerular basement membrane, which is a more diffuse pattern of scarring. This is less specific than nodular glomerulosclerosis, which is the more defining feature of diabetic kidney disease. C. Armani-Ebstein reaction This option is incorrect. The Armani-Ebstein reaction refers to degenerative changes in the proximal renal tubular epithelium, typically seen in cases of chronic kidney disease or end-stage renal failure. It is characterized by lipid accumulation in the tubular cells and is not specific to diabetic nephropathy. While kidney damage can occur in diabetes, the Armani-Ebstein reaction is not the hallmark of diabetic nephropathy. D. Fibrin caps This option is incorrect. Fibrin caps are fibrin deposits that may appear in certain types of glomerular diseases, such as glomerulonephritis, but they are not characteristic of diabetic nephropathy. Diabetic nephropathy is more classically associated with nodular glomerulosclerosis, which is a specific pattern of glomerular damage seen in the disease.",
      "correct_choice_id": 225949,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36587121704443714/36587121704443714.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36587121704443714/36587121704443714.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94493,
      "choices": [
        {
          "id": 225952,
          "text": "Insulinoma"
        },
        {
          "id": 225953,
          "text": "Accidental sulfonylurea ingestion"
        },
        {
          "id": 225954,
          "text": "Accidental exogenous insulin administration"
        },
        {
          "id": 225955,
          "text": "Accidental metformin ingestion"
        }
      ],
      "text": "A patient presents with symptoms of hypoglycaemia investigations reveal decreased blood glucose and increased insulin levels. C-peptide assay is done which shows normal level of C-peptide. The most likely diagnosis is",
      "unique_key": "Q7288423",
      "question_audio": null,
      "question_video": null,
      "map_id": 34456110,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Accidental exogenous insulin administration. In this case, the patient presents with symptoms of hypoglycemia, which is characterized by low blood glucose and elevated insulin levels. However, the normal C-peptide level is a key finding. C-peptide is produced in equal amounts as insulin when the pancreas releases endogenous insulin. If the insulin levels are high and the C-peptide level is normal, it indicates that the source of insulin is exogenous (i.e., from an external source like injected insulin) rather than endogenous production by the pancreas. Therefore, the most likely cause of the hypoglycemia in this patient is accidental exogenous insulin administration, where the patient has unintentionally injected insulin, leading to hypoglycemia. Incorrect Answers A. Insulinoma This option is incorrect. Insulinoma is a pancreatic tumor that produces excess insulin, causing hypoglycemia. In patients with insulinoma, you would expect to see elevated insulin levels along with high C-peptide levels, since the insulin is produced by the pancreas. In this case, the normal C-peptide level rules out insulinoma as the cause of the hypoglycemia. B. Accidental sulfonylurea ingestion This option is incorrect. Sulfonylureas are oral medications that stimulate the pancreas to release insulin. If a patient ingests sulfonylureas, they would typically have increased insulin levels along with increased C-peptide levels, because the pancreas is stimulated to release its own insulin. The normal C-peptide level in this case makes sulfonylurea ingestion an unlikely cause of hypoglycemia. D. Accidental metformin ingestion This option is incorrect. Metformin is an oral medication used to treat type 2 diabetes, and it does not cause hypoglycemia. Metformin works by improving insulin sensitivity and reducing glucose production in the liver, but it does not increase insulin secretion. Therefore, metformin ingestion would not result in increased insulin levels or hypoglycemia.",
      "correct_choice_id": 225954,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43219301704443725/43219301704443725.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43219301704443725/43219301704443725.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94494,
      "choices": [
        {
          "id": 225956,
          "text": "Type I diabetes"
        },
        {
          "id": 225957,
          "text": "Type II diabetes"
        },
        {
          "id": 225958,
          "text": "Malnutrition related type disease"
        },
        {
          "id": 225959,
          "text": "Pregnancy related type diabetes"
        }
      ],
      "text": "Which type of diabetes is HLA associated:",
      "unique_key": "Q3786893",
      "question_audio": null,
      "question_video": null,
      "map_id": 34624029,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Type I diabetes. Type 1 diabetes is HLA (Human Leukocyte Antigen) associated. This autoimmune form of diabetes occurs when the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. The HLA gene plays a significant role in regulating the immune system, and certain HLA genotypes, particularly HLA-DR3 and HLA-DR4, have been strongly linked to an increased risk of developing type 1 diabetes. These genetic factors predispose individuals to autoimmune processes that result in the destruction of pancreatic beta cells, leading to insulin deficiency. Incorrect Answers B. Type II diabetes This option is incorrect. Type 2 diabetes is not directly associated with HLA. It is primarily related to insulin resistance and a relative insulin deficiency, often in the context of obesity and other lifestyle factors. Although genetics do play a role in the development of type 2 diabetes, it is not specifically linked to the HLA genes. Rather, it is associated with other genetic and environmental factors such as diet, physical activity, and family history. C. Malnutrition related type disease This option is incorrect. Malnutrition-related diabetes (also known as maturity-onset diabetes of the young, or MODY) occurs due to various forms of insulin resistance or defective insulin secretion caused by genetic mutations. This type of diabetes is not associated with HLA but is usually related to specific genetic mutations that affect insulin production or function. D. Pregnancy-related type diabetes This option is incorrect. Gestational diabetes, or pregnancy-related diabetes, typically develops during pregnancy and is characterized by insulin resistance. It is not directly linked to HLA. Instead, the condition is often associated with hormonal changes during pregnancy that interfere with insulin's ability to function effectively, and factors like obesity and family history of type 2 diabetes increase the risk.",
      "correct_choice_id": 225956,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/670691704443736/670691704443736.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/670691704443736/670691704443736.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94495,
      "choices": [
        {
          "id": 225960,
          "text": "Hydrochlorothiazide"
        },
        {
          "id": 225961,
          "text": "Enalapril"
        },
        {
          "id": 225962,
          "text": "Amiloride"
        },
        {
          "id": 225963,
          "text": "Aspirin"
        }
      ],
      "text": "A 50 year old male with type 2 diabetes mellitus is found to have 24-hour urinary albumin of 250 mg. Which of the following drugs may be used to retard progression of renal disease?",
      "unique_key": "Q3604692",
      "question_audio": null,
      "question_video": null,
      "map_id": 34904829,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Enalapril. In patients with type 2 diabetes mellitus and proteinuria (albuminuria), such as this patient with a 24-hour urinary albumin of 250 mg, the use of angiotensin-converting enzyme inhibitors (ACE inhibitors) like Enalapril is recommended to retard the progression of diabetic nephropathy. ACE inhibitors help lower blood pressure, reduce proteinuria, and provide renoprotection by dilating the efferent arteriole in the kidney, thus reducing glomerular pressure and further kidney damage. Enalapril specifically has proven efficacy in slowing the progression of kidney disease in diabetic patients and improving outcomes. Incorrect Answers A. Hydrochlorothiazide This option is incorrect. Hydrochlorothiazide is a thiazide diuretic, which can be used to treat hypertension but does not have the same direct protective effect on the kidneys as ACE inhibitors. While controlling blood pressure is important in managing diabetic nephropathy, thiazide diuretics do not directly reduce proteinuria or slow the progression of renal disease as effectively as ACE inhibitors. C. Amiloride This option is incorrect. Amiloride is a potassium-sparing diuretic, typically used in combination with other diuretics to prevent hypokalemia. It does not have the renoprotective effects seen with ACE inhibitors like Enalapril. While amiloride may be helpful in certain situations, it is not the drug of choice to retard the progression of diabetic nephropathy or reduce albuminuria. D. Aspirin This option is incorrect. Aspirin is an anti-inflammatory and antiplatelet drug, commonly used for cardiovascular protection, especially in diabetic patients with a high risk of cardiovascular disease. However, aspirin does not have a direct effect on kidney function or proteinuria in the context of diabetic nephropathy. While aspirin may help reduce the risk of heart disease, it is not used to slow the progression of renal disease in diabetic nephropathy.",
      "correct_choice_id": 225961,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62590151704443768/62590151704443768.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62590151704443768/62590151704443768.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94496,
      "choices": [
        {
          "id": 225964,
          "text": "Add metformin"
        },
        {
          "id": 225965,
          "text": "Add ACE inhibitors"
        },
        {
          "id": 225966,
          "text": "Lifestyle modifications"
        },
        {
          "id": 225967,
          "text": "All the above"
        }
      ],
      "text": "A 50-year-old man is visiting OPD multiple times for last 6 months with history of increased thirst. The patient has had BP readings of 134/86 mm Hg, 148/96 mm Hg, and 142/90 mm Hg on the last three visits. He has been reluctant to start antihypertensive medications and, instead, has been trying to correct it with exercise and weight loss. His weight has increased by 2 kg. He doesn’t take alcohol and is non-smoker. There is no other significant past medical history. Family h/o-father has coronary artery disease. On examination, BP: 144/92 mm Hg, Heart, Lung, Abdomen: normal findings. Lab reports-plasma random glucose 218 mg/dL; blood urea nitrogen 22 g/dL; creatinine 0.7 mg/dL; CBC: normal, HbA1c: 8.4%, serum LDL cholesterol 145 mg/dL. Urine for microalbumin 120 mg/g. What will you do next",
      "unique_key": "Q2088658",
      "question_audio": null,
      "question_video": null,
      "map_id": 34831395,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All the above. This patient presents with increased thirst, elevated blood pressure, elevated HbA1c (8.4%), and plasma glucose levels (218 mg/dL), which are indicative of poorly controlled type 2 diabetes. Additionally, his microalbuminuria (120 mg/g) suggests the early signs of diabetic nephropathy. In light of this, the most appropriate approach is a combination of lifestyle modifications, pharmacologic management of hypertension, and the management of hyperglycemia. Lifestyle modifications (e.g., diet, exercise, weight loss) remain the cornerstone of management for both hypertension and diabetes. This is especially important for weight loss, which may improve both blood glucose and blood pressure control. Metformin is the first-line treatment for type 2 diabetes due to its ability to reduce hepatic glucose production and improve insulin sensitivity. His HbA1c of 8.4% indicates that his blood glucose is not well-controlled, and initiating metformin would be beneficial. ACE inhibitors (e.g., ramipril, lisinopril) should be added to manage his hypertension and to offer renal protection, especially given the presence of microalbuminuria. ACE inhibitors have proven benefits in diabetic nephropathy and in controlling blood pressure in diabetic patients. Given that he has hypertension, type 2 diabetes, and early signs of diabetic nephropathy, all these interventions are indicated. Reasons for Correct and Incorrect Options: A. Add metformin – Correct: Metformin is the first-line therapy for managing type 2 diabetes. This patient has a plasma glucose of 218 mg/dL and an HbA1c of 8.4%, indicating poorly controlled diabetes. Metformin improves insulin sensitivity, decreases hepatic glucose production, and has cardiovascular benefits. It should be initiated as part of the treatment plan for this patient. B. Add ACE inhibitors – Correct: ACE inhibitors, such as lisinopril or enalapril, are beneficial for hypertension management, especially in patients with diabetes and microalbuminuria. These drugs not only help control blood pressure but also reduce the progression of diabetic nephropathy by decreasing albumin excretion. This patient's urine microalbumin is elevated (120 mg/g), which suggests early kidney damage, and ACE inhibitors will protect the kidneys in addition to lowering blood pressure. C. Lifestyle modifications – Correct: Lifestyle changes, including weight loss, exercise, and dietary modifications, are essential for managing both hypertension and diabetes. They should be implemented alongside pharmacologic therapy to achieve optimal control of both blood pressure and blood glucose. Weight loss is particularly important for improving insulin sensitivity and managing blood pressure. D. All the above – Correct: The correct approach involves a combination of lifestyle modifications, metformin for diabetes management, and ACE inhibitors for both blood pressure control and kidney protection. Together, these interventions address all aspects of the patient's care, including hypertension, hyperglycemia, and renal protection.",
      "correct_choice_id": 225967,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9850701705043306/9850701705043306.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9850701705043306/9850701705043306.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94497,
      "choices": [
        {
          "id": 225968,
          "text": "Check Hba1c to see average improvement in plasma glucose"
        },
        {
          "id": 225969,
          "text": "Increase ramipril dose"
        },
        {
          "id": 225970,
          "text": "Increase atorvastatin"
        },
        {
          "id": 225971,
          "text": "Stop metformin in view of weight loss"
        }
      ],
      "text": "In continuation of previous question,patient was started on metformin,ramipril and atorvastatin.The patient comes for follow up visit after 2 weeks.His symptoms of thirst and polyuria have already improved.He is fully adherent to lifestyle modifications and medicines.You check his BP which is 140/92 mm Hg.His weight is reduced by 2 kg.What will you do next",
      "unique_key": "Q4165566",
      "question_audio": null,
      "question_video": null,
      "map_id": 34908673,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Increase ramipril dose. The patient has shown improvement in symptoms of thirst and polyuria, indicating better blood glucose control. However, his blood pressure remains 140/92 mm Hg, which is still above the recommended target of <130/80 mm Hg for individuals with diabetes. Since he is adherent to his medications and lifestyle modifications, the next step would be to increase the dose of his ramipril, an ACE inhibitor, to better control his hypertension. Optimizing blood pressure is essential to reduce the risk of cardiovascular complications and diabetic nephropathy. Reasons for Correct and Incorrect Options: A. Check HbA1c to see average improvement in plasma glucose – Incorrect: While monitoring HbA1c is important in diabetes management, the patient has already shown improvement in his symptoms of thirst and polyuria, which strongly suggests that his blood glucose control is improving. Given that he is already on metformin and lifestyle modifications, it would be more appropriate to focus on managing his blood pressure at this point, especially since his blood pressure is still above the target. B. Increase ramipril dose – Correct: The patient’s blood pressure of 140/92 mm Hg is still above the goal of <130/80 mm Hg for patients with diabetes. ACE inhibitors, like ramipril, are first-line agents for managing hypertension in diabetic patients and also offer renal protection. Since the patient is adhering to both medications and lifestyle modifications, the next step would be to increase the dose of ramipril or consider adding another antihypertensive if the blood pressure remains elevated. C. Increase atorvastatin – Incorrect: The patient’s serum LDL cholesterol was noted to be 145 mg/dL earlier, and atorvastatin was initiated as part of his cardiovascular risk management. However, the current focus should be on blood pressure rather than increasing atorvastatin, since his cholesterol management is already underway. LDL cholesterol levels are not typically adjusted frequently unless there is an issue with the current dose or further risk factors are present. The priority should be improving his blood pressure control first. D. Stop metformin in view of weight loss – Incorrect: The patient’s weight loss of 2 kg is a positive sign, indicating improvement in lifestyle modifications and better blood glucose control. Metformin is a weight-neutral medication and does not need to be stopped due to weight loss. In fact, it is beneficial for both blood glucose control and weight management in type 2 diabetes, so continuing metformin is the right approach.",
      "correct_choice_id": 225969,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40318351705043318/40318351705043318.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40318351705043318/40318351705043318.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94498,
      "choices": [
        {
          "id": 225972,
          "text": "Diagnose the patient as having diabetes mellitus"
        },
        {
          "id": 225973,
          "text": "Confirm with oral glucose tolerance test with 75 gm glucose"
        },
        {
          "id": 225974,
          "text": "Get a fasting plasma glucose"
        },
        {
          "id": 225975,
          "text": "Start the patient on insulin"
        }
      ],
      "text": "A 45 year old female recently diagnosed with type 2 diabetes. She has classical symptoms of weight loss, polydipsia and polyuria. Her plasma glucose is 212 g/dl and 240 g/dl on 2 separate occasions. She has sedentary lifestyle with type A personality. She has no other significant past medical history. She has 2 children without any complications or gestational diabetes during pregnancy. Family history-not significant. On examination her weight is 95 kg with BMI 32,BP-140/88 mmHg. She has acanthosis nigricans, otherwise rest of physical examination is normal. Based on this information what will you do next?",
      "unique_key": "Q3120385",
      "question_audio": null,
      "question_video": null,
      "map_id": 34099399,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Diagnose the patient as having diabetes mellitus. This patient presents with classical symptoms of type 2 diabetes (weight loss, polydipsia, polyuria) along with plasma glucose readings of 212 mg/dL and 240 mg/dL on two separate occasions. According to the American Diabetes Association (ADA) criteria, a diagnosis of diabetes mellitus can be made with a plasma glucose ≥ 200 mg/dL on random testing, or with an elevated fasting plasma glucose ≥ 126 mg/dL or an oral glucose tolerance test (OGTT) ≥ 200 mg/dL. Given that this patient has a plasma glucose > 200 mg/dL on two separate occasions and presents with symptoms of hyperglycemia, she meets the criteria for diagnosis of diabetes mellitus without the need for further testing. Reasons for Correct and Incorrect Options: A. Diagnose the patient as having diabetes mellitus This patient meets the diagnostic criteria for diabetes mellitus based on her symptoms and plasma glucose levels of 212 mg/dL and 240 mg/dL on separate occasions. The presence of polydipsia, polyuria, and weight loss further supports the diagnosis. Therefore, no further tests are required to make the diagnosis at this time. B. Confirm with oral glucose tolerance test with 75 gm glucose Although the oral glucose tolerance test (OGTT) is a diagnostic tool for diabetes, it is not necessary in this case because the patient already meets the criteria for diabetes mellitus based on her plasma glucose levels (>200 mg/dL) and the presence of symptoms. Therefore, there is no need to conduct an OGTT. C. Get a fasting plasma glucose A fasting plasma glucose (FPG) test is useful for diagnosing diabetes or pre-diabetes, but in this case, the patient already has elevated plasma glucose levels that meet the diagnostic criteria for diabetes. Since the patient already has a plasma glucose >200 mg/dL with symptoms of hyperglycemia, confirming with an FPG is not necessary for diagnosis at this point. D. Start the patient on insulin Starting insulin is not the first-line treatment for newly diagnosed type 2 diabetes. For most patients with type 2 diabetes, initial treatment typically includes lifestyle changes (diet and exercise) and oral medications (like metformin). Insulin is usually reserved for patients who cannot achieve glycemic control with oral agents or when there is significant hyperglycemia requiring rapid reduction. This patient should begin with lifestyle modifications and consider oral medications such as metformin for initial management, not insulin.",
      "correct_choice_id": 225972,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69561421705127915/69561421705127915.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69561421705127915/69561421705127915.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94499,
      "choices": [
        {
          "id": 225976,
          "text": "Dilation of afferent arteriole increases glomerular filtration rate."
        },
        {
          "id": 225977,
          "text": "Dilation of efferent arteriole decreases glomerular hypertension."
        },
        {
          "id": 225978,
          "text": "Decreased BP protects the tubules."
        },
        {
          "id": 225979,
          "text": "Aldosterone inhibition affects the kidney."
        }
      ],
      "text": "A 40-year-old male with history of type 2 diabetes for 5 years presented with frothing in urine. He is taking metformin for diabetes. On examination BP is 126/80 mmHg,BMI-30, Other systemic examination is normal. Lab results – HbA1c-7.8 %, serum creatinine- 1.4 mg/dl, urine for microalbumin 250 mg/g. You start the patient on ramipril for microalbuminuria. What is the mechanism of ACE inhibitor benefit for microalbuminuria?",
      "unique_key": "Q9909185",
      "question_audio": null,
      "question_video": null,
      "map_id": 34540569,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Dilation of efferent arteriole decreases glomerular hypertension. In patients with microalbuminuria, particularly in those with diabetes, the glomerulus can become hyperfiltrative, which increases the pressure in the glomerular capillaries (glomerular hypertension). This increased pressure can lead to further kidney damage, including the development of proteinuria and albuminuria. ACE inhibitors, like ramipril, primarily work by dilating the efferent arteriole of the glomerulus. This dilation helps reduce the intraglomerular pressure, thereby decreasing glomerular hypertension and the associated damage to the kidneys. This mechanism is particularly beneficial in microalbuminuria and can slow the progression of diabetic nephropathy. Reasons for Correct and Incorrect Options: B. Dilation of efferent arteriole decreases glomerular hypertension – Correct: The key therapeutic benefit of ACE inhibitors in patients with microalbuminuria lies in their ability to dilate the efferent arteriole of the glomerulus. This action reduces glomerular pressure, which in turn decreases the leakage of albumin into the urine. By lowering glomerular hypertension, ACE inhibitors help to protect the kidneys and reduce proteinuria in conditions like diabetic nephropathy. A. Dilation of afferent arteriole increases glomerular filtration rate – Incorrect: While dilation of the afferent arteriole can increase glomerular filtration rate (GFR), this is not the primary mechanism by which ACE inhibitors benefit patients with microalbuminuria. In fact, dilating the afferent arteriole may increase glomerular pressure, which could worsen kidney damage in certain conditions. The main beneficial effect of ACE inhibitors is the dilation of the efferent arteriole, not the afferent arteriole. C. Decreased BP protects the tubules – Incorrect: While ACE inhibitors can lower blood pressure, which in turn helps protect the kidneys, this is not the primary mechanism for improving microalbuminuria. The major benefit of ACE inhibitors in this context is the effect on glomerular pressure, not simply blood pressure reduction. Although lowering blood pressure is beneficial for kidney function, it is the effect on glomerular hypertension via the efferent arteriole dilation that specifically targets albuminuria. D. Aldosterone inhibition affects the kidney – Incorrect: While ACE inhibitors can also inhibit aldosterone to some extent, this is not their primary mechanism in the treatment of microalbuminuria. The primary mechanism remains the dilation of the efferent arteriole and the subsequent reduction in glomerular hypertension. Aldosterone inhibition does contribute to the kidney-protective effects of ACE inhibitors, but it is secondary to the effects on glomerular pressure.",
      "correct_choice_id": 225977,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12583501705043354/12583501705043354.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12583501705043354/12583501705043354.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94500,
      "choices": [
        {
          "id": 225980,
          "text": "Sulfonylurea"
        },
        {
          "id": 225981,
          "text": "Pioglitazone"
        },
        {
          "id": 225982,
          "text": "GLP-1 agonist"
        },
        {
          "id": 225983,
          "text": "SGLT inhibitors"
        }
      ],
      "text": "A 68 year old man diagnosed as having type 2 diabetes, hypertension, dyslipidemia, CHF and microalbuminuria. The patient is given prescriptions for lisinopril, metformin,thiazide and a statin. A prescription is also given for a home BP monitor and fingerstick glucose monitoring. He tend to skip his meals. He returns in 4 weeks and his BP is 130/80 mm Hg. There is mild pedal edema, lungs/heart examination is normal. His home random glucose test results are: 182 mg/dL, 170 mg/dL, 184 mg/dL, 165 mg/dL. Liver and kidney function tests are normal. Because the patient’s glucose levels are not fully controlled on metformin, you want to add a second agent. He is not willing for any injectable therapy. What will be next appropriate agent",
      "unique_key": "Q1080954",
      "question_audio": null,
      "question_video": null,
      "map_id": 34430473,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) SGLT inhibitors. Given that this patient has type 2 diabetes, hypertension, dyslipidemia, CHF, and microalbuminuria, choosing an appropriate second-line agent is critical. The patient is already on metformin, and his blood glucose is still elevated, with random glucose levels ranging from 165 to 184 mg/dL. In this case, the most suitable second-line therapy is an SGLT-2 inhibitor, such as empagliflozin or canagliflozin, due to their dual benefits in lowering blood glucose and providing kidney and heart protection. SGLT-2 inhibitors work by preventing glucose reabsorption in the kidneys, leading to its excretion in the urine. Additionally, they have been shown to improve cardiovascular outcomes and renal function in patients with heart failure and diabetic nephropathy (microalbuminuria). These benefits make them a particularly good choice for patients with heart failure (as in this case) and kidney concerns. Reasons for Correct and Incorrect Options: D. SGLT inhibitors – Correct: SGLT-2 inhibitors (like empagliflozin or canagliflozin) are the preferred choice here due to their multifaceted benefits: Blood glucose control – They effectively lower blood glucose levels by promoting renal glucose excretion. Cardiovascular protection – Studies like the EMPA-REG OUTCOME trial and CANVAS trial have shown significant benefits in reducing heart failure symptoms, improving cardiac outcomes, and preventing cardiovascular events in patients with diabetes and heart failure. Renal protection – They also reduce albuminuria, providing benefits for diabetic nephropathy (which this patient has). This makes SGLT-2 inhibitors an ideal choice, particularly in patients with heart failure and kidney involvement. A. Sulfonylurea – Incorrect: Sulfonylureas (like glimepiride or glyburide) are oral agents that stimulate insulin secretion from the pancreas. While they are effective in lowering blood glucose, they can cause hypoglycemia and weight gain, both of which are undesirable in this patient, particularly considering his heart failure and possible renal concerns. Additionally, sulfonylureas do not have the same cardiovascular or renal protective benefits that SGLT-2 inhibitors offer. B. Pioglitazone – Incorrect: Pioglitazone is a thiazolidinedione that works by improving insulin sensitivity. While it may be effective in controlling blood glucose, it is associated with weight gain, fluid retention, and increased risk of heart failure, making it a less ideal choice for this patient with CHF. Additionally, it does not provide the same cardiovascular or renal protection that SGLT-2 inhibitors do. C. GLP-1 agonist – Incorrect: GLP-1 receptor agonists (like liraglutide or semaglutide) are injectable agents that improve insulin secretion, reduce glucagon release, and slow gastric emptying, leading to lower blood glucose levels. While they can be effective, the patient specifically does not want injectable therapy, so this option would not be appropriate. Moreover, they do not have the same renal protective benefits as SGLT-2 inhibitors, though they can provide cardiovascular protection in some patients.",
      "correct_choice_id": 225983,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48643651705043372/48643651705043372.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48643651705043372/48643651705043372.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94501,
      "choices": [
        {
          "id": 225984,
          "text": "No additional treatment needed"
        },
        {
          "id": 225985,
          "text": "Add sitagliptin and calcium channel blocker"
        },
        {
          "id": 225986,
          "text": "Add Telmisartan"
        },
        {
          "id": 225987,
          "text": "Add betablocker"
        }
      ],
      "text": "A 54-year-old man, who was diagnosed with diabetes last year, comes to your OPD for a follow-up appointment. He was placed on metformin and a sulfonylurea, which controlled his glucose levels for most of the last year. Currently, he has started to have some episodes of nocturia one to two times a night. He insists he is fully adherent to his medications and lifestyle modifications. Past medical history: Hypertension, Hyperlipidemia, Microalbuminuria, Medications: Metformin, atorvastatin, lisinopril, glimepiride. Current BP – 146/92 mmHg, HbA1c: 7.8% Serum glucose: 195 mg/dL, positive urine microalbumin, liver function tests are normal, LDL: 80 mg/dL. What will you do next",
      "unique_key": "Q5623877",
      "question_audio": null,
      "question_video": null,
      "map_id": 34679870,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Add sitagliptin and calcium channel blocker. In this case, the patient has type 2 diabetes, which is not well-controlled with a HbA1c of 7.8%, and he is experiencing nocturia. This indicates that his glucose levels are still elevated, as evidenced by the serum glucose of 195 mg/dL, and he is at risk for microalbuminuria progression (since he has a positive urine microalbumin test). His hypertension and microalbuminuria make it important to adjust his treatment strategy to target both glucose control and kidney protection. The patient is currently on metformin and a sulfonylurea (glimepiride), which are useful but may not be sufficient for optimal glucose control over time. Sitagliptin, a DPP-4 inhibitor, can be added to improve glucose control by increasing incretin levels, enhancing insulin secretion in response to meals, and reducing glucagon release. DPP-4 inhibitors have the advantage of being oral agents, which is a plus for patient adherence. Additionally, the patient has microalbuminuria, which indicates early kidney damage. The calcium channel blocker (CCB) can help with blood pressure control, especially since this patient’s blood pressure is still elevated at 146/92 mmHg, despite being on lisinopril. CCBs like amlodipine or diltiazem may be beneficial because they also help in reducing proteinuria and can provide further renal protection. Reasons for Correct and Incorrect Options: B. Add sitagliptin and calcium channel blocker – Correct: This approach addresses both glucose control and renal protection. Sitagliptin helps improve glucose control, and calcium channel blockers help lower blood pressure and reduce proteinuria. The combination of these drugs is appropriate given the patient's microalbuminuria and hypertension. Both treatment components align well with evidence-based guidelines for managing diabetes and kidney disease. A. No additional treatment needed – Incorrect: Given the patient's current HbA1c of 7.8%, which is above the target range for most diabetic patients (typically <7%), more intensive treatment is required to achieve better glucose control. Additionally, his nocturia suggests that his glucose is not adequately managed. Therefore, no additional treatment is not appropriate. C. Add Telmisartan – Incorrect: While Telmisartan (an ARB) could help with both blood pressure control and renal protection (by reducing proteinuria), this patient is already on lisinopril (an ACE inhibitor), which has similar effects on the renin-angiotensin system. Adding another RAAS inhibitor (like telmisartan) could increase the risk of hyperkalemia and acute kidney injury, especially in the context of renal disease. The patient would benefit from enhancing glucose control and BP management with other options rather than just adding a second RAAS inhibitor. D. Add beta-blocker – Incorrect: A beta-blocker is typically used for patients with heart disease or arrhythmias, and while it can help with blood pressure control, it does not directly address the patient’s glucose control or microalbuminuria. Given the patient's comorbidities, a calcium channel blocker is a more appropriate choice for both BP and renal protection. A beta-blocker does not add significant benefits in this specific case.",
      "correct_choice_id": 225985,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11414761705043397/11414761705043397.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11414761705043397/11414761705043397.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94502,
      "choices": [
        {
          "id": 225988,
          "text": "Insulin"
        },
        {
          "id": 225989,
          "text": "HCO3"
        },
        {
          "id": 225990,
          "text": "Antibiotics"
        },
        {
          "id": 225991,
          "text": "IV fluids"
        }
      ],
      "text": "A 34-year-old man with a history of type 1 diabetes is brought to the ED by his family for confusion and lethargy for the last day. The patient has been a lifelong diabetic who also has some unclear psychiatric issues. The family says he stopped taking his insulin a few days ago for unclear reasons—he may have just run out of his medications. R: 34 breaths/minute; BP: 106/68 mm Hg; P: 122 beats/minute; T: 99.8°F. PE: General: lethargic, disoriented, rolling around in bed, respiratory distress Chest: clear to auscultation Abdomen: soft, nontender Cardiovascular: no murmur, no gallop Neurological: unable to determine whether there are focal deficits. Glucose 725 mg/dL Bicarbonate 12 mEq/L Chloride 100 mEq/L K 6.4 mEq/L Sodium 126 mEq/L ABG: pH 7.12; partial pressure of carbon dioxide (PCO2 ) 28 mm Hg; partial pressure of oxygen (PO2 ) 95 mm Hg UA: glucose 1000 mg/dL; ketones +++ Acetone, beta-hydroxybutyrate levels: markedly elevated ECG: sinus tachycardia, normal T wave, no ST abnormalities What will be the immediate next step",
      "unique_key": "Q1267386",
      "question_audio": null,
      "question_video": null,
      "map_id": 34102704,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) IV fluids. This patient presents with hyperglycemia (glucose 725 mg/dL), metabolic acidosis (bicarbonate 12 mEq/L, pH 7.12), and ketonuria (+++) with symptoms of confusion, lethargy, and respiratory distress. This clinical picture is highly suggestive of diabetic ketoacidosis (DKA), a life-threatening complication of type 1 diabetes. The immediate management of DKA primarily involves fluid resuscitation to correct hypovolemia, improve renal perfusion, and reduce the effects of hyperglycemia and ketone production. The elevated sodium and increased potassium levels indicate electrolyte imbalances, which can worsen with inadequate hydration. IV fluids (typically normal saline) are the cornerstone of initial treatment, as they help in restoring intravascular volume and improving renal clearance of glucose and ketones. Reasons for Correct and Incorrect Options: D. IV fluids – Correct: The first step in the management of DKA is fluid resuscitation. This helps to correct dehydration, lower blood glucose levels, and promote renal excretion of glucose and ketones. In addition, IV fluids help restore circulating volume, which improves renal function and allows for more effective administration of insulin later on. Therefore, IV fluids are the immediate priority in this patient's care. A. Insulin – Incorrect: While insulin is crucial in the treatment of DKA, it is not the first step. Fluid resuscitation should be initiated first to correct dehydration, as administering insulin in a dehydrated state could worsen the situation by further dropping the patient's blood pressure and impairing renal function. Once fluid status is addressed, insulin can be started to correct the hyperglycemia and stop ketone production. B. HCO3 – Incorrect: Administering bicarbonate (HCO3) is generally not recommended in DKA, unless the patient's pH is extremely low (<6.9). This patient has a pH of 7.12, which, although low, is not an indication for bicarbonate therapy. The goal in DKA treatment is to correct the underlying issue with insulin and fluids. Bicarbonate can worsen hypokalemia and other electrolyte imbalances, and its routine use in DKA is discouraged. C. Antibiotics – Incorrect: This patient does not show signs of an infection (fever, chills, localized symptoms) that would warrant the use of antibiotics. Although infections are a common precipitating factor for DKA, there is no evidence from the patient's history or physical exam suggesting an active infection at this time. Therefore, antibiotics are not needed in the immediate management.",
      "correct_choice_id": 225991,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75445731705044130/75445731705044130.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75445731705044130/75445731705044130.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94503,
      "choices": [
        {
          "id": 225992,
          "text": "Stop IV insulin; switch to subcutaneous delivery."
        },
        {
          "id": 225993,
          "text": "Switch to oral fluids."
        },
        {
          "id": 225994,
          "text": "Add potassium to fluids."
        },
        {
          "id": 225995,
          "text": "Move the patient out of ICU."
        }
      ],
      "text": "In continuation of previous case patient was started on iv fluids along with insulin infusion. After 2 hours, the patient’s lethargy resolves, and normal mentation returns. The repeat laboratory test results are: Glucose 245 mg/dL K 4.8 mEq/L Serum bicarbonate 18 mEq/L pH 7.32 What is the biggest change you must make in management?",
      "unique_key": "Q8162570",
      "question_audio": null,
      "question_video": null,
      "map_id": 34504042,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Add potassium to fluids. This patient has shown significant improvement after 2 hours of IV fluids and insulin therapy. The glucose has decreased to 245 mg/dL, and lethargy has resolved, indicating that the initial treatment has been effective in addressing the hyperglycemia and acidosis. However, the potassium level has dropped to 4.8 mEq/L, which is on the lower end of normal, especially considering that during the treatment of diabetic ketoacidosis (DKA), potassium levels often decrease due to the effect of insulin driving potassium into cells and fluid resuscitation. As such, the next step in management is to add potassium to the IV fluids to prevent hypokalemia, which can lead to arrhythmias and other complications. Reasons for Correct and Incorrect Options: C. Add potassium to fluids – Correct: When managing DKA, especially after the initial correction with insulin and fluids, the body can experience shifts of potassium from the extracellular space to the intracellular space, resulting in a drop in serum potassium levels. Even if the potassium is initially within normal limits, it can fall quickly during treatment. Since this patient’s potassium is now on the lower end of normal (4.8 mEq/L), adding potassium to the IV fluids is crucial to prevent hypokalemia and ensure that the patient’s potassium levels remain stable as treatment progresses. A. Stop IV insulin; switch to subcutaneous delivery – Incorrect: Although the patient’s mental status has improved, IV insulin should not be stopped yet. In DKA, insulin therapy should continue until the glucose is well controlled, the anion gap has closed, and the patient is no longer in metabolic acidosis. Switching to subcutaneous insulin would be premature because the insulin infusion is still necessary to maintain control over the hyperglycemia and ketosis. Transitioning to subcutaneous insulin should only occur once the patient has stabilized and is no longer in acute DKA. B. Switch to oral fluids – Incorrect: Although the patient is improving, it is still too early to switch to oral fluids. In DKA, patients often remain in a hypovolemic state even after initial fluid resuscitation. Additionally, oral intake may not be sufficient to meet the patient's needs until they are fully stable, and the risk of electrolyte imbalances or glucose fluctuations still exists. Hence, IV fluids should be continued, especially to ensure that potassium levels are corrected. D. Move the patient out of ICU – Incorrect: This patient has made progress, but DKA is a serious condition, and the patient is still at risk of electrolyte imbalances, fluid shifts, and hypoglycemia. ICU care is still necessary to monitor the patient closely, manage the insulin infusion, and ensure electrolyte correction. The patient should only be moved out of the ICU once metabolic stability is achieved, including normal glucose levels, resolution of acidosis, and stable electrolytes.",
      "correct_choice_id": 225994,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2419791705044148/2419791705044148.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2419791705044148/2419791705044148.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94504,
      "choices": [
        {
          "id": 225996,
          "text": "It is a laboratory artifact."
        },
        {
          "id": 225997,
          "text": "Chloride interferes with sodium measurement."
        },
        {
          "id": 225998,
          "text": "Hyperglycemia pulls water out of cells, diluting out the sodium."
        },
        {
          "id": 225999,
          "text": "Sodium loss in urine."
        }
      ],
      "text": "A 64-year-old man with a history of type 2 diabetes presented to emergency with polyuria, confusion and lethargy for the few day. He stopped taking his medications for 2 weeks. His oral intake is low. On examination-BP-100/60 mmHg, disoriented, ,Chest: clear to auscultation Abdomen: soft, nontender Cardiovascular: no murmur, no gallop. Plasma Glucose 660 mg/dL, Chloride 100 mEq/L, Sodium 125 mEq/L, ABG: pH 7.3; ketones- negative, ECG: sinus tachycardia. What is the mechanism of this decrease in sodium?",
      "unique_key": "Q9531717",
      "question_audio": null,
      "question_video": null,
      "map_id": 34096569,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Hyperglycemia pulls water out of cells, diluting out the sodium. In this patient with severe hyperglycemia (660 mg/dL), the primary cause of low sodium is the effect of hyperglycemia on water distribution. Hyperglycemia leads to an osmotic diuresis that causes water to shift from the intracellular space into the extracellular space, leading to dilution of sodium in the blood. This phenomenon is a key feature of hyperosmolar hyperglycemic state (HHS), a complication seen in patients with poorly controlled type 2 diabetes. As water is drawn out of cells and into the extracellular space to balance the osmotic gradient, the sodium concentration becomes diluted, resulting in hyponatremia. Reasons for Correct and Incorrect Options: C. Hyperglycemia pulls water out of cells, diluting out the sodium – Correct: In HHS or severe hyperglycemia, the elevated glucose levels lead to an osmotic gradient that draws water out of the cells and into the bloodstream. This fluid shift dilutes the sodium levels in the extracellular space, causing pseudohyponatremia. This is a well-known mechanism for low sodium in the setting of hyperglycemia and is commonly seen in diabetic emergencies such as HHS. A. It is a laboratory artifact – Incorrect: While laboratory artifacts can cause inaccurate sodium readings, the clinical scenario in this patient suggests that the low sodium is due to osmotic dilution from hyperglycemia rather than a laboratory error. There is no indication in the question suggesting any problem with the laboratory procedure or equipment, making this option unlikely. B. Chloride interferes with sodium measurement – Incorrect: This statement is incorrect as chloride does not interfere with sodium measurements in clinical practice. Both sodium and chloride are measured independently in standard laboratory tests. The electrolyte disturbances in this case are a result of hyperglycemia and osmotic effects, not due to interference from chloride levels. The sodium concentration is decreased because of the water shift due to high glucose levels, not because of any interference in the measurement. D. Sodium loss in urine – Incorrect: Although sodium loss in urine can contribute to hyponatremia, the primary cause of the low sodium in this patient is due to hyperglycemia causing an osmotic shift of water into the extracellular space, which dilutes the sodium concentration. There is no indication that this patient is experiencing significant sodium loss through the kidneys. In fact, HHS typically presents with dehydration, not with significant sodium depletion in the urine.",
      "correct_choice_id": 225998,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15214861705044165/15214861705044165.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15214861705044165/15214861705044165.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94505,
      "choices": [
        {
          "id": 226000,
          "text": "Insulin like growth factor (IGF)"
        },
        {
          "id": 226001,
          "text": "GH"
        },
        {
          "id": 226002,
          "text": "MRI head"
        },
        {
          "id": 226003,
          "text": "Glucose suppression test"
        }
      ],
      "text": "A 48-year-old man with hypertension and diabetes comes to the OPD because he has daytime somnolence and his wife complains that he snores, has body odor and having erectile dysfunction. Shoe and ring size started increasing over the last 1 to 2 years. On examination BP: 160/100 mm Hg; General appearance: large nose, lips, and jaw; teeth widely spaced. Thyromegaly present. Chest-clear, CVS- normal. What is the best initial test?",
      "unique_key": "Q7671041",
      "question_audio": null,
      "question_video": null,
      "map_id": 34789138,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Insulin-like growth factor (IGF). This patient presents with acromegalic features, including enlargement of facial features (large nose, lips, jaw), increased shoe and ring size, daytime somnolence, snoring, and erectile dysfunction. These findings are indicative of growth hormone (GH) excess, which is often due to a pituitary adenoma. The best initial test for diagnosing acromegaly is to measure insulin-like growth factor (IGF-1). IGF-1 levels are elevated in most patients with acromegaly and are a more stable marker of GH secretion than random GH levels. High levels of IGF-1 suggest the presence of acromegaly and further testing (such as GH suppression tests or imaging) would be required to confirm the diagnosis and localize the source. Incorrect Options: B. GH – Incorrect: Measuring growth hormone (GH) levels is not the best initial test because GH levels fluctuate throughout the day and can be influenced by various factors (e.g., stress, exercise, glucose levels). Instead, IGF-1, which reflects the chronic levels of GH, provides a more reliable and stable measurement for diagnosing acromegaly. C. MRI head – Incorrect: While an MRI of the head is useful for identifying a pituitary adenoma after acromegaly is confirmed, it is not the initial diagnostic test. Before proceeding to imaging, biochemical confirmation of GH excess through IGF-1 levels is required. Imaging is done after an elevated IGF-1 level confirms the diagnosis to help localize the tumor. D. Glucose suppression test – Incorrect: The glucose suppression test is used to assess for growth hormone excess but is not the initial test. In this test, a glucose load normally suppresses GH secretion in healthy individuals, but in acromegaly, GH suppression is impaired. However, because IGF-1 levels are a more reliable indicator of GH excess, the glucose suppression test is typically done after an elevated IGF-1 level to confirm the diagnosis.",
      "correct_choice_id": 226000,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37822491705044241/37822491705044241.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37822491705044241/37822491705044241.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94506,
      "choices": [
        {
          "id": 226004,
          "text": "Na replacement"
        },
        {
          "id": 226005,
          "text": "K replacement"
        },
        {
          "id": 226006,
          "text": "IV dextrose"
        },
        {
          "id": 226007,
          "text": "IV calcium"
        }
      ],
      "text": "A 43-year-old man comes to clinic because of progressive slowness due muscle weakness. It is equal in all four extremities, started 6 months ago, and is slowly progressive and uncomfortable. There is h/o polyuria also. BP: 168/98 mm Hg; P: 72 beats/minute. Cardiovascular: S4 gallop Musculoskeletal: decreased strength throughout. Lab reports- sodium 145 mEq/L; K: 2.4 mEq/L, ECG: U waves present, T4 , TSH, CBC, calcium, phosphorus: normal. You start the treatment and in 2 days patient weakness has improved and U waves in ECG disappeared. What was the treatment ?",
      "unique_key": "Q4103253",
      "question_audio": null,
      "question_video": null,
      "map_id": 34943347,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) K replacement. This patient presents with symptoms of muscle weakness, polyuria, and ECG changes (U waves) associated with hypokalemia. The lab results show a serum potassium level of 2.4 mEq/L, which is markedly low. Hypokalemia can lead to muscle weakness, arrhythmias (such as U waves on ECG), and cardiovascular abnormalities. The rapid improvement in the patient's condition following treatment strongly suggests that potassium replacement was the correct intervention. Potassium replacement helps correct the hypokalemia, leading to improved muscle strength and resolution of ECG changes (such as the U waves). Incorrect Options: A. Na replacement – Incorrect: Although sodium imbalances can cause neurological and cardiovascular symptoms, the patient's sodium level is 145 mEq/L, which is within the normal range. There is no indication that sodium replacement is necessary. The main issue here is the low potassium rather than a sodium deficit. C. IV dextrose – Incorrect: IV dextrose is typically used for managing hypoglycemia or to treat certain metabolic disorders like diabetic ketoacidosis or hyperosmolar hyperglycemic state. There is no indication of hypoglycemia or need for glucose infusion in this patient. The primary issue here is hypokalemia, not low blood sugar. D. IV calcium – Incorrect: IV calcium is used to treat conditions like hypocalcemia or cardiac arrhythmias associated with low calcium levels. This patient’s calcium level is normal, so there is no need for IV calcium. The issue here is hypokalemia, which is treated with potassium replacement, not calcium replacement.",
      "correct_choice_id": 226005,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45101831705044293/45101831705044293.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45101831705044293/45101831705044293.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94507,
      "choices": [
        {
          "id": 226008,
          "text": "Hypokalemic periodic paralysis"
        },
        {
          "id": 226009,
          "text": "Hyperkalemic periodic paralysis"
        },
        {
          "id": 226010,
          "text": "Myasthenia Gravis as its also autoimmune"
        },
        {
          "id": 226011,
          "text": "Hypocalcemia"
        }
      ],
      "text": "Patient started on oral antithyroid drug- carbimazole as she refused other form of treatment. But she didn’t come for regular follow up. One year later she complaint of multiple episodes of muscle weakness following excess oral carbohydrate. Each episode of Weakness lasted for 48 hours then subsided. Which is the likely cause of her weakness",
      "unique_key": "Q8915929",
      "question_audio": null,
      "question_video": null,
      "map_id": 34379942,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Hypokalemic periodic paralysis. This patient with Graves' disease who was started on carbimazole but missed regular follow-up may now be experiencing hypokalemic periodic paralysis (HPP), a condition characterized by recurrent episodes of muscle weakness due to low potassium levels. These episodes are often triggered by factors such as excessive carbohydrate intake, exercise, or stress, leading to potassium shift into cells and causing a temporary hypokalemia. The weakness typically resolves after a few hours to a couple of days as potassium levels normalize. Graves' disease and the use of antithyroid drugs like carbimazole are both associated with electrolyte disturbances. Although HPP is more commonly seen in patients with hyperthyroidism, it is especially prevalent in young males, though it can also affect females. The characteristic pattern of muscle weakness triggered by carbohydrate intake, which lasts for 48 hours, is very suggestive of hypokalemic periodic paralysis, which is often self-limiting and responds to potassium supplementation. Incorrect Options: B. Hyperkalemic periodic paralysis – Incorrect: Hyperkalemic periodic paralysis (HKPP) is another form of periodic paralysis but is characterized by episodes of muscle weakness with elevated potassium levels rather than low levels. The weakness typically follows exercise, rest after exercise, or stress, and is associated with elevated serum potassium during attacks. This patient's clinical presentation and the typical hypokalemia make HPP more likely than HKPP. C. Myasthenia Gravis as it's also autoimmune – Incorrect: Although Myasthenia Gravis (MG) is an autoimmune condition, it primarily causes fatigable muscle weakness due to impaired neuromuscular transmission, typically affecting the ocular and bulbar muscles first, and then proximal muscles. The weakness in MG worsens with activity and improves with rest, rather than being triggered by carbohydrate intake and lasting for 48 hours. Furthermore, carbimazole does not typically induce MG-like symptoms, making this an unlikely diagnosis in this case. D. Hypocalcemia – Incorrect: Hypocalcemia can lead to muscle cramps, tetany, and in severe cases, seizures, but it does not typically present with the intermittent episodes of muscle weakness seen in this patient. The episodes triggered by carbohydrate intake and lasting for 48 hours are more indicative of hypokalemic periodic paralysis, not hypocalcemia. Additionally, hypocalcemia is typically associated with other symptoms such as chvostek's sign or trousseau's sign, which are not noted here.",
      "correct_choice_id": 226008,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75156731705044409/75156731705044409.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75156731705044409/75156731705044409.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94508,
      "choices": [
        {
          "id": 226012,
          "text": "Pioglitazone"
        },
        {
          "id": 226013,
          "text": "Sitagliptin."
        },
        {
          "id": 226014,
          "text": "Insulin glargine"
        },
        {
          "id": 226015,
          "text": "Metformin"
        }
      ],
      "text": "A 50-year-old woman presented in your OPD with Fasting blood glucose of 160 mg/dL and 155 mg/dL on two occasions. HgA1c is 7.9%. You educate the patient on medical nutrition therapy. She returns for reevaluation in 8 weeks. She states she has followed diet and exercise recommendations, but her FBG remains between 140 and 150 and HgA1C is 7.7%. She is asymptomatic, and physical examination shows no abnormalities. Which of the following is the treatment of choice?",
      "unique_key": "Q2550782",
      "question_audio": null,
      "question_video": null,
      "map_id": 34186011,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Metformin. In this patient with type 2 diabetes mellitus (T2DM), lifestyle modification (medical nutrition therapy and exercise) has not resulted in adequate glycemic control, as evidenced by the fasting blood glucose (FBG) levels of 140-150 mg/dL and HbA1c of 7.7%. The next step in treatment is to initiate pharmacologic therapy. Metformin is the first-line medication for most patients with T2DM, particularly in those who are overweight or obese, as in this case (no weight information provided, but typically, metformin is recommended in these scenarios). Metformin works by reducing hepatic glucose production and increasing insulin sensitivity. It is effective, well-tolerated, and low-cost. It has the added benefit of weight neutrality and may promote modest weight loss, making it an ideal choice for patients struggling with glucose control despite lifestyle changes. The American Diabetes Association (ADA) and other clinical guidelines recommend metformin as the first-line agent for managing T2DM in such cases. Incorrect Responses: A. Pioglitazone – Incorrect: Pioglitazone is a thiazolidinedione (TZD) that increases insulin sensitivity in peripheral tissues. While effective, pioglitazone is not first-line therapy due to potential side effects, including weight gain, fluid retention, and a slight increase in the risk of heart failure. It may also cause bone loss in women. Therefore, metformin is preferred over pioglitazone unless there are contraindications to metformin use. B. Sitagliptin – Incorrect: Sitagliptin is a DPP-4 inhibitor that increases insulin secretion in response to meals and decreases glucagon secretion. While it is an effective agent and has a good safety profile, it is typically considered a second-line agent when metformin alone does not achieve adequate control. It is more expensive than metformin and generally reserved for cases where metformin is contraindicated or not well-tolerated. Thus, metformin is the preferred first-line treatment. C. Insulin glargine – Incorrect: Insulin glargine is a long-acting insulin that provides basal insulin coverage. While it is effective in lowering blood glucose, the goal in the early stages of type 2 diabetes is generally to avoid initiating insulin therapy unless absolutely necessary (e.g., in cases of symptomatic hyperglycemia or marked glucose elevation). Oral medications like metformin should be tried first, especially since insulin therapy often requires frequent blood glucose monitoring and can result in weight gain and hypoglycemia. Insulin therapy would be considered later if the patient’s glucose control remains inadequate with oral agents.",
      "correct_choice_id": 226015,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75192381705045471/75192381705045471.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75192381705045471/75192381705045471.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94509,
      "choices": [
        {
          "id": 226016,
          "text": "Lithium"
        },
        {
          "id": 226017,
          "text": "Cyclophosphamide"
        },
        {
          "id": 226018,
          "text": "Barbiturates"
        },
        {
          "id": 226019,
          "text": "Nicotine"
        }
      ],
      "text": "A 33-year-old man is complaining of feeling thirsty all the time and passing more urine than usual. His physical examination is normal. His serum sodium is 150 mEq/L, glucose 120 mg/dL, and osmolality 315 mOsm/kg. The urine sodium is 20 mEq/L and osmolality 260 mOsm/kg. Which of the following drugs is most likely to cause this disorder?",
      "unique_key": "Q4686081",
      "question_audio": null,
      "question_video": null,
      "map_id": 34470976,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Lithium. This patient is presenting with symptoms of polyuria, polydipsia, hypernatremia, and inappropriately dilute urine (urine osmolality of 260 mOsm/kg in the context of hyperosmolar serum), which suggests a diagnosis of diabetes insipidus (DI). The likely cause of his condition is lithium, a medication commonly associated with nephrogenic diabetes insipidus (NDI). Lithium impairs the kidney's ability to respond to antidiuretic hormone (ADH), leading to reduced water reabsorption and polyuria. The urine sodium is elevated (20 mEq/L), which suggests a kidney that is still responding to sodium, but the inability to concentrate urine points towards nephrogenic DI caused by lithium. Incorrect Answers: B. Cyclophosphamide: Cyclophosphamide is a chemotherapy drug, but it is not a common cause of nephrogenic diabetes insipidus. While cyclophosphamide can cause bladder toxicity and other side effects, it is not typically associated with polyuria and polydipsia due to impaired renal water reabsorption. C. Barbiturates: Barbiturates can depress the central nervous system and cause sedation, but they are not typically associated with nephrogenic diabetes insipidus or the findings of hypernatremia and inappropriately dilute urine as seen in this case. D. Nicotine: Nicotine is a stimulant that affects the central nervous system and has various cardiovascular effects, but it does not typically lead to nephrogenic diabetes insipidus or interfere with the kidney's ability to concentrate urine as seen with lithium.",
      "correct_choice_id": 226016,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/68207221705047862/68207221705047862.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/68207221705047862/68207221705047862.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94510,
      "choices": [
        {
          "id": 226020,
          "text": "Renal disease"
        },
        {
          "id": 226021,
          "text": "Diabetes insipidus"
        },
        {
          "id": 226022,
          "text": "Alzheimer’s disease"
        },
        {
          "id": 226023,
          "text": "Anorexia"
        }
      ],
      "text": "A 63-year-old man develops severe pain, redness, and swelling in his left big toe. Past medical history is positive for type 2 diabetes, CAD and hypertension. He is smoker and drinks alcohol daily. On examination left great toe is tender with erythema.BP-160/100 mmHg. Blood tests showed elevated LDL cholesterol and serum uric acid. Which of the following conditions is most likely associated with this condition?",
      "unique_key": "Q6474423",
      "question_audio": null,
      "question_video": null,
      "map_id": 34215742,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) This 63-year-old man presents with a classic case of gout, characterized by severe pain, redness, and swelling in the left big toe, which is a common presentation of acute gouty arthritis. Gout is caused by the deposition of uric acid crystals in the joints, leading to inflammation. The elevated serum uric acid level and his history of type 2 diabetes, CAD, and hypertension make gout likely, as these conditions are associated with hyperuricemia (high serum uric acid levels), which is the primary risk factor for gout. Patients with renal disease are at higher risk for gout because impaired renal function leads to reduced excretion of uric acid. The kidneys are responsible for eliminating most of the uric acid from the body, and when kidney function is compromised, uric acid accumulates in the blood, increasing the risk of gout. Given the patient's age, comorbidities, and elevated uric acid levels, renal disease is the most likely associated condition. Explanation of Incorrect Answers: B. Diabetes insipidus: Diabetes insipidus (DI) is a disorder characterized by excessive thirst and urination, usually caused by a deficiency in antidiuretic hormone (ADH) or resistance to it. DI does not cause elevated serum uric acid or increase the risk of gout. In fact, patients with diabetes insipidus often experience dehydration, which might result in concentrated urine, but it is unrelated to the development of gout. Therefore, DI is not associated with this patient’s gouty symptoms. C. Alzheimer’s disease: Alzheimer’s disease is a neurodegenerative disorder that affects memory and cognitive function, but it is not related to gout or uric acid metabolism. Alzheimer's is not typically associated with elevated serum uric acid or conditions that promote gout. There is no direct link between gout and Alzheimer's disease, so this option is not correct. D. Anorexia: While anorexia nervosa can cause a range of metabolic disturbances, including electrolyte imbalances, it is not directly associated with gout. Anorexia typically leads to low uric acid levels due to starvation and malnutrition, which is the opposite of the situation in gout. In this patient, the high uric acid levels make anorexia an unlikely cause of his condition.",
      "correct_choice_id": 226020,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11255011705048150/11255011705048150.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11255011705048150/11255011705048150.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94511,
      "choices": [
        {
          "id": 226024,
          "text": "A urine osmolality"
        },
        {
          "id": 226025,
          "text": "Hemoglobin A1C level"
        },
        {
          "id": 226026,
          "text": "A fasting blood sugar (FBS)"
        },
        {
          "id": 226027,
          "text": "A glucose tolerance test (GTT)"
        }
      ],
      "text": "A 57-year-old man complains of increased thirst and urination. He has to wake up 3-4 times in night. He noticed blurring of vision for last 3 months. His father and brother has type 2 diabetes. He is sedentary. In last one year his stress levels are increased due to job profile. His examination showed acanthosis nigricans and obesity (BMI>30). Which of the following is the most appropriate initial diagnostic test?",
      "unique_key": "Q6027064",
      "question_audio": null,
      "question_video": null,
      "map_id": 34878869,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) A fasting blood sugar (FBS) Explanation of Correct Answer: This 57-year-old man presents with symptoms of increased thirst, urination, and blurry vision, all of which are common symptoms of hyperglycemia. His family history of type 2 diabetes and other risk factors such as obesity (BMI > 30), sedentary lifestyle, and acanthosis nigricans further increase the suspicion of type 2 diabetes. The most appropriate initial diagnostic test to evaluate for diabetes is a fasting blood sugar (FBS). The FBS test is used to determine if the blood glucose level is elevated in a fasting state, which is a key diagnostic criterion for diabetes. According to the American Diabetes Association (ADA), a fasting blood glucose level of 126 mg/dL or higher on two separate occasions is diagnostic of diabetes. Explanation of Incorrect Answers: A. A urine osmolality: While urine osmolality testing can be useful in certain situations like evaluating diabetes insipidus, it is not the most appropriate test for diagnosing type 2 diabetes. In this patient's case, the more direct approach would be to check his blood glucose levels using a fasting blood sugar (FBS) test. Urine osmolality (A) is not typically used for diagnosing diabetes mellitus. B. Hemoglobin A1C level: Although hemoglobin A1C is an important test for diagnosing diabetes and monitoring long-term glucose control, it is generally used after initial suspicion of diabetes has been established through blood glucose testing. While it could be considered, fasting blood sugar (FBS) is the more straightforward and commonly used initial test. An A1C of 6.5% or greater is diagnostic for diabetes, but it's not typically the first test ordered when symptoms are present. D. A glucose tolerance test (GTT): The glucose tolerance test (GTT) is a more complex test that involves drinking a glucose solution and testing blood glucose at intervals afterward. While it is a diagnostic tool for gestational diabetes and impaired glucose tolerance, it is usually not the first-line test for a patient presenting with classic symptoms of hyperglycemia, such as increased thirst and urination. The fasting blood sugar (FBS) is more appropriate as the initial diagnostic test.",
      "correct_choice_id": 226026,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28032261705048222/28032261705048222.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28032261705048222/28032261705048222.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94512,
      "choices": [
        {
          "id": 226028,
          "text": "Diabetes mellitus"
        },
        {
          "id": 226029,
          "text": "Diabetes insipidus"
        },
        {
          "id": 226030,
          "text": "Pheochromocytoma"
        },
        {
          "id": 226031,
          "text": "Myxedema"
        }
      ],
      "text": "A 55-year-old obese woman complains of dry mouth, excessive urination. He has lost 5 kg weight in last 3 months in spite of large appetite. She has vulvar pruritus with white curdy discharge. There are symptoms of numbness in hands and feet. There is family history diabetes mellitus in siblings. Which of the following is the most likely diagnosis?",
      "unique_key": "Q8364499",
      "question_audio": null,
      "question_video": null,
      "map_id": 34037602,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Diabetes mellitus Explanation of Correct Answer: The patient presents with a classic set of symptoms that strongly suggest diabetes mellitus: Dry mouth and excessive urination (polyuria), which are both common symptoms of uncontrolled hyperglycemia. Weight loss despite increased appetite (polyphagia), which is often seen in diabetes mellitus as the body cannot properly utilize glucose, leading to catabolism and weight loss. Vulvar pruritus with white curdy discharge, which is consistent with a vaginal yeast infection, a common complication of diabetes mellitus due to high blood sugar levels promoting fungal overgrowth. Numbness in hands and feet (peripheral neuropathy), another complication of diabetes mellitus that results from long-term hyperglycemia affecting the nerves. Additionally, the family history of diabetes mellitus in her siblings further supports the diagnosis of diabetes mellitus, which has a strong genetic component. Given these clinical features, diabetes mellitus is the most likely diagnosis. Explanation of Incorrect Answers: B. Diabetes insipidus: While diabetes insipidus also presents with symptoms of polyuria and polydipsia (increased thirst), it is caused by either a deficiency of antidiuretic hormone (ADH) or resistance to it, leading to large volumes of dilute urine. However, the patient's weight loss, vulvar pruritus with curdy discharge, and numbness in hands and feet do not align with the diagnosis of diabetes insipidus. Additionally, diabetes insipidus is typically not associated with significant changes in blood glucose levels, which is a key feature in diabetes mellitus. C. Pheochromocytoma: A pheochromocytoma is a rare tumor of the adrenal gland that produces excess catecholamines (adrenaline and noradrenaline). It typically presents with symptoms such as hypertension, headache, sweating, and palpitations, but not the symptoms described in this patient, such as weight loss despite large appetite, vulvar pruritus, or numbness in hands and feet. The patient's presentation is more consistent with diabetes mellitus than a pheochromocytoma. D. Myxedema: Myxedema refers to severe hypothyroidism, which can present with symptoms like fatigue, weight gain, cold intolerance, dry skin, and slow heart rate. However, this patient's weight loss, increased appetite, and vulvar pruritus with white curdy discharge are more indicative of diabetes mellitus, and not of hypothyroidism. Additionally, myxedema does not cause numbness in hands and feet in the same way that diabetes mellitus does with peripheral neuropathy.",
      "correct_choice_id": 226028,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10418961705048321/10418961705048321.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10418961705048321/10418961705048321.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94513,
      "choices": [
        {
          "id": 226032,
          "text": "Erythema nodosum"
        },
        {
          "id": 226033,
          "text": "Pyoderma gangreosum"
        },
        {
          "id": 226034,
          "text": "Necrobiosis lipoidica"
        },
        {
          "id": 226035,
          "text": "Erythema multiforme"
        }
      ],
      "text": "A 72-year-old man with Type 2 diabetes for last 10 years. He notices painless skin lesions on his legs.On examination BP-150/100 mmHg,pulse is 90/min,afebrile.Local examination of leg showed an irregular raised border with a flat depressed center that is hyperpigmented brown in color.Lab tests- HbA1c-9.6%,fasting plasma glucose 200 mg/dl,CBC is normal.What is the likely diagnosis",
      "unique_key": "Q7358552",
      "question_audio": null,
      "question_video": null,
      "map_id": 34788539,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Necrobiosis lipoidica Explanation of Correct Answer: The presentation of irregular raised border with a flat, depressed center that is hyperpigmented brown in color on the legs in a patient with Type 2 diabetes is highly suggestive of necrobiosis lipoidica. This condition is often associated with diabetes mellitus, particularly with poorly controlled blood glucose as indicated by his elevated HbA1c (9.6%) and fasting plasma glucose (200 mg/dl). Necrobiosis lipoidica typically presents as shiny, atrophic, hyperpigmented plaques with a yellowish center, often on the shins. These lesions can be mistaken for other skin conditions, but they are more commonly seen in patients with diabetes, especially those with poor glycemic control. This diagnosis fits the patient's clinical scenario. Explanation of Incorrect Answers: A. Erythema nodosum: Erythema nodosum presents as painful, red, tender nodules usually on the shins, with an associated inflammatory reaction. This condition is often linked to infections, inflammatory bowel disease, or certain medications, but it does not typically present with painless lesions or the raised border with a flat depressed center described in this patient. The absence of pain and the specific lesion morphology makes erythema nodosum less likely. B. Pyoderma gangrenosum: Pyoderma gangrenosum usually presents with rapidly enlarging painful ulcerations with an undermined edge. It is associated with systemic conditions such as inflammatory bowel disease or rheumatoid arthritis. The lesion in this patient is not ulcerated, and the morphology does not match that of pyoderma gangrenosum, making this diagnosis unlikely. Also, the painless nature of the lesion makes it less compatible with pyoderma gangrenosum. D. Erythema multiforme: Erythema multiforme typically presents with target-like lesions (central blister with a surrounding ring), which are often associated with infections (especially Herpes simplex virus). The lesion described here has an irregular raised border with a flat depressed center and is hyperpigmented, not characteristic of the target lesions seen in erythema multiforme. This patient's lesion does not fit the typical presentation of erythema multiforme.",
      "correct_choice_id": 226034,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52180951705048337/52180951705048337.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52180951705048337/52180951705048337.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94514,
      "choices": [
        {
          "id": 226036,
          "text": "Microaneurysms"
        },
        {
          "id": 226037,
          "text": "Dilated veins"
        },
        {
          "id": 226038,
          "text": "Hemorrhage (dot and blot)"
        },
        {
          "id": 226039,
          "text": "All"
        }
      ],
      "text": "A 60-year-old man with Type 2 diabetes comes for routine check up. Physical examination is normal. Blood tests revealed HbA1c 8.0%,urine albumin creatinine ratio 400 mg/g. You advised him to go for fundus check up. The ophthalmologist reports that the patient has developed non proliferative retinopathy. What can be the possible findings in retina",
      "unique_key": "Q7012932",
      "question_audio": null,
      "question_video": null,
      "map_id": 34327007,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All Explanation of Correct Answer: In non-proliferative diabetic retinopathy, the microvascular changes seen in the retina are often early signs of diabetic retinopathy and are primarily caused by the effects of hyperglycemia on the small blood vessels of the retina. The typical findings include: Microaneurysms, which are small, localized bulges in the retinal blood vessels. Dilated veins as a result of poor retinal circulation and venous congestion. Hemorrhages (dot and blot) due to the rupture of the weakened microvasculature, which leads to leakage of blood into the retina. All of these findings are characteristic of non-proliferative diabetic retinopathy and can be seen in a patient with poorly controlled Type 2 diabetes, as in this case. Hence, all of the listed findings are possible in this patient's retina, making option D (All) the most appropriate answer. Explanation of Incorrect Answers: A. Microaneurysms: While microaneurysms are a hallmark feature of non-proliferative retinopathy, they are just one of several findings. The presence of microaneurysms alone does not capture the full spectrum of changes that occur in the retina during non-proliferative diabetic retinopathy, which can also include dilated veins and hemorrhages. B. Dilated veins: Dilated veins are another feature of non-proliferative diabetic retinopathy, but they are part of the broader spectrum of changes in the retina and not the sole defining feature. Therefore, this option is incomplete as it does not address the full range of findings in non-proliferative retinopathy. C. Hemorrhage (dot and blot): Hemorrhages, specifically dot and blot hemorrhages, are also characteristic of non-proliferative diabetic retinopathy due to the rupture of the small blood vessels in the retina. However, focusing on only hemorrhages omits other key findings, like microaneurysms and dilated veins, that can also be present.",
      "correct_choice_id": 226039,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19409131705048349/19409131705048349.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19409131705048349/19409131705048349.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94515,
      "choices": [
        {
          "id": 226040,
          "text": "Microaneurysms"
        },
        {
          "id": 226041,
          "text": "Vitreal hemorrhage"
        },
        {
          "id": 226042,
          "text": "Dilated veins"
        },
        {
          "id": 226043,
          "text": "Dot and blot hemorrhage"
        }
      ],
      "text": "A 35-year-old woman with Type 1 diabetes for 20 years. She has uncontrolled glucose and complaint of osmotic symptoms and frothy urine. She was also diagnosed with diabetes nephropathy last year. Now she develops progressive vision loss in her left eye. The ophthalmologist reports the development of proliferative retinopathy. What will be likely findings in retina",
      "unique_key": "Q5340246",
      "question_audio": null,
      "question_video": null,
      "map_id": 34843755,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Vitreal hemorrhage Explanation of Correct Answer: In proliferative diabetic retinopathy (PDR), the most significant and concerning finding is the growth of new, abnormal blood vessels on the retina and vitreous, a condition known as neovascularization. These new vessels are fragile and prone to bleeding, leading to vitreal hemorrhage (bleeding into the vitreous humor of the eye). This can result in progressive vision loss, as seen in this patient who has a history of diabetic nephropathy and is experiencing uncontrolled glucose levels. The vitreal hemorrhage associated with proliferative retinopathy can cause blurred vision and may lead to further complications such as retinal detachment. Explanation of Incorrect Answers: A. Microaneurysms: Microaneurysms are characteristic of non-proliferative diabetic retinopathy, which is an earlier stage of diabetic retinopathy. While they are a hallmark of the non-proliferative stage, they are not the primary feature of proliferative retinopathy. In proliferative retinopathy, the focus is on neovascularization and vitreal hemorrhages rather than microaneurysms. C. Dilated veins: Dilated veins are a feature of non-proliferative diabetic retinopathy and are indicative of venous stasis or poor circulation. However, in proliferative diabetic retinopathy, the predominant concern is the development of neovascularization, which can lead to complications such as vitreal hemorrhage and retinal detachment, rather than dilated veins. D. Dot and blot hemorrhage: Dot and blot hemorrhages are typically seen in the non-proliferative stage of diabetic retinopathy and are indicative of leakage from microvascular damage. In proliferative diabetic retinopathy, although hemorrhages may still occur, the more significant finding is vitreal hemorrhage due to the fragile new vessels formed during neovascularization.",
      "correct_choice_id": 226041,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3246211705048371/3246211705048371.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3246211705048371/3246211705048371.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94516,
      "choices": [
        {
          "id": 226044,
          "text": "Hypokalemia"
        },
        {
          "id": 226045,
          "text": "Hypochloremia"
        },
        {
          "id": 226046,
          "text": "Metabolic alkalosis"
        },
        {
          "id": 226047,
          "text": "Hyperglycemia"
        }
      ],
      "text": "A 17-year-old man is brought to the emergency room because of weakness and weight loss. He is diagnosed with an eating disorder and admitted to the hospital. He is cachexic, dry skin, brittle hairs, BP-80/50 mmHg, pulse 60/min, chest-clear, CVS-normal, per abdomen is soft. Which of the following lab values is not consistent with this diagnosis?",
      "unique_key": "Q3832982",
      "question_audio": null,
      "question_video": null,
      "map_id": 34376422,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Hyperglycemia Explanation of Correct Answer: The patient's symptoms, including cachexia, dry skin, brittle hair, low blood pressure, and bradycardia, are highly suggestive of anorexia nervosa, an eating disorder characterized by severe calorie restriction, excessive exercise, and a distorted body image. Individuals with anorexia nervosa often develop hypokalemia, hypochloremia, and metabolic alkalosis due to vomiting, excessive use of laxatives, or diuretic abuse. These compensatory mechanisms, in response to the starvation and electrolyte imbalances, lead to low levels of potassium, chloride, and alkalosis. However, hyperglycemia is not typically associated with anorexia nervosa. In fact, individuals with severe malnutrition and caloric restriction often experience hypoglycemia due to the body’s inability to maintain adequate glucose levels during periods of fasting. The absence of adequate nutritional intake leads to decreased glycogen stores and decreased insulin sensitivity, often resulting in low blood glucose levels rather than high. Therefore, hyperglycemia would not be a typical laboratory finding in a patient with anorexia nervosa and is the correct answer. Explanation of Incorrect Answers: A. Hypokalemia: Hypokalemia (low potassium levels) is a common finding in patients with anorexia nervosa, especially in those who engage in vomiting, diuretic abuse, or excessive exercise. Vomiting leads to loss of both potassium and chloride through gastric contents, contributing to electrolyte imbalances, including hypokalemia. This would be expected in this patient. B. Hypochloremia: Hypochloremia (low chloride levels) often accompanies hypokalemia in patients with anorexia nervosa who have been vomiting or using diuretics. Vomiting causes the loss of chloride in addition to potassium, leading to low levels of both electrolytes. It is consistent with this patient's presentation and would be an expected lab finding. C. Metabolic alkalosis: Metabolic alkalosis is often observed in patients with anorexia nervosa due to vomiting or excessive use of diuretics. Both conditions lead to loss of hydrogen ions (acid) from the body, which causes the blood pH to rise, resulting in alkalosis. The lab results in this patient are likely to show a metabolic alkalosis, especially with the history of starvation and potential purging behaviors.",
      "correct_choice_id": 226047,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20830451705048406/20830451705048406.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20830451705048406/20830451705048406.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 94517,
      "choices": [
        {
          "id": 226048,
          "text": "Acute glomerulonephritis"
        },
        {
          "id": 226049,
          "text": "Obstructive uropathy"
        },
        {
          "id": 226050,
          "text": "Glomerulosclerosis with mesangial thickening"
        },
        {
          "id": 226051,
          "text": "Polycystic kidneys"
        }
      ],
      "text": "A 64-year woman with Type 2 diabetes for 10 years now develops increasing fatigue, dyspnea, and pedal edema. On examination, her blood pressure is 166/90 mm Hg, pulse 90/min, JVP is 4 cm above sternal angle, heart sounds are normal, lungs are clear, and there is 3+ pedal edema. HbA1c is 8.5 %,fasting plasma glucose is 180 mg/dl. Her urinalysis is positive for 3+ protein and no casts. Which of the following renal diseases is the most likely diagnosis in this patient?",
      "unique_key": "Q4787559",
      "question_audio": null,
      "question_video": null,
      "map_id": 34479596,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Glomerulosclerosis with mesangial thickening Explanation of Correct Answer: This patient with Type 2 diabetes for 10 years, presenting with fatigue, dyspnea, and pedal edema, is likely suffering from diabetic nephropathy. The key findings in her clinical presentation include proteinuria (3+ on urinalysis) and elevated blood pressure (166/90 mm Hg), which are classic signs of chronic kidney disease (CKD). Glomerulosclerosis with mesangial thickening is a characteristic feature of diabetic nephropathy and is commonly seen in patients with long-standing diabetes. In diabetic nephropathy, the glomeruli undergo thickening of the mesangial matrix, leading to impaired filtration and proteinuria. Hypertension and diabetic control (HbA1c of 8.5%) contribute to the progression of the disease, resulting in worsening renal function and edema. Explanation of Incorrect Answers: A. Acute glomerulonephritis: Acute glomerulonephritis typically presents with acute onset of symptoms like hematuria, proteinuria, oliguria, and often hypertension. However, the patient's history of long-standing Type 2 diabetes, and the absence of symptoms such as hematuria or casts on urinalysis, make acute glomerulonephritis an unlikely diagnosis. This is more consistent with chronic renal disease seen in diabetic nephropathy. B. Obstructive uropathy: Obstructive uropathy is typically characterized by urinary retention, dilated renal collecting system, and hydronephrosis. While this patient has pedal edema, which could suggest fluid retention, her clinical findings do not support obstructive uropathy, such as a history of anatomic obstruction (e.g., prostatic disease, stones, or strictures). Furthermore, her normal urinalysis findings (no casts) are more consistent with diabetic nephropathy. D. Polycystic kidneys: Polycystic kidney disease (PKD) typically presents with enlarged kidneys and cyst formation. While it can lead to renal dysfunction and proteinuria, the absence of family history or signs of cystic renal disease (such as palpable masses) and the patient’s long-standing diabetes make PKD less likely. In this case, diabetic nephropathy with glomerulosclerosis and mesangial thickening is a more plausible diagnosis.",
      "correct_choice_id": 226050,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2475551705048440/2475551705048440.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2475551705048440/2475551705048440.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}